16.55
-2.07%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anhui Huaheng Biotechnology Co
Its shares trade on Shanghai under the ticker 688639.SS. It has been listed since 22 April 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.86bn and net income of CN¥132.4m. At that date it held total assets of CN¥5.77bn and shareholders' equity of CN¥2.65bn.
Anhui Huaheng Biotechnology Co., Ltd. engages in the research, development, production, and sale of amino acids and its derivatives. The company is headquartered in Hefei, Anhui. The company went IPO on 2021-04-22. The firm is a high-tech enterprise focusing on synthetic biotechnology and mainly engaged in the research and development, production and sales of amino acid and its derivative products. The firm's main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin. The firm's products are mainly used in the fields of medicine and health products, daily chemicals, food and food additives. The firm distributes its products and services within the domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 22 Apr 2021
- Employees
- 995
- Website
- huahengbio.com ↗
Leadership
Pay as last reported
- Ms. Henghua GuoChairman of the Board, General Manager, since 2013
- Mr. Yi FanFinance Director, Deputy General Manager, Secretary of the Board, Director, since 2016
- Mr. Dongzhu ZhangDeputy General Manager, Director, since 2007
- Mr. Zhongcheng LiuDeputy General Manager
- Mr. Fanbao MengDeputy General Manager
- Mr. Hengping GuoDirector
- Mr. Jianwen MaoDirector
- Mr. Xueli ZhangDirector
- Mr. Fucai WangIndependent Director
- Mr. Lin WuIndependent Director
- Mr. Qifeng ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- High-tech enterprise with 995 employees focused on synthetic biotechnology.
- Main products include alanine series and calcium D-pantothenate for health and food sectors.
- Diverse product range used in medicine, daily chemicals, and food additives.
Weaknesses
- IPO listed on 22 April 2021 with no mention of recent financial performance.
- Limited domestic market focus without specific overseas market share data.
- No mention of R&D investment or innovation pipeline beyond current products.
Opportunities
- Growing demand for amino acid derivatives in health and food industries globally.
- Expansion into new markets for synthetic biotechnology applications.
- Increased focus on biotechnology in China's Materials sector.
Threats
- Competition from other chemical companies in the Materials sector.
- Regulatory changes affecting chemical production in China.
- Dependence on domestic market with limited international presence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.